Regulatory Fast Track and Merger Make GPC Biotech AG (GPCB) ADR an Attractive Investment
The United States Food and Drug Administration (FDA) has put an experimental drug from one of the company’s key research programs on a fast track for approval. The European Commission has taken similar action by granting one of this company's discoveries special status. Discounted values of future cash flows from this ADR have improved considerably as a result of the rapid progress the company has made in the new drug development and approval processes. The Biotechnology & Drugs Industry is normally beset with investment risks, since regulators refuse approvals for so many candidate drugs. The chances of this company making…